Show simple item record

dc.contributor.authorHuang, Zheng-jiezh_CN
dc.contributor.authorZhao, Yilinzh_CN
dc.contributor.authorLuo, Wei-yuanzh_CN
dc.contributor.authorYou, Junzh_CN
dc.contributor.authorLi, Shui-wenzh_CN
dc.contributor.authorYi, Wen-chengzh_CN
dc.contributor.authorWang, Sheng-yuzh_CN
dc.contributor.authorYan, Jiang-huazh_CN
dc.contributor.authorLuo, Qizh_CN
dc.contributor.author黄正接zh_CN
dc.contributor.author赵一麟zh_CN
dc.contributor.author尤俊zh_CN
dc.contributor.author颜江华zh_CN
dc.contributor.author罗琪zh_CN
dc.date.accessioned2015-07-22T07:36:59Z
dc.date.available2015-07-22T07:36:59Z
dc.date.issued2013zh_CN
dc.identifier.citationSCIENTIFIC WORLD JOURNAL, 2013zh_CN
dc.identifier.otherWOS:000321373500001zh_CN
dc.identifier.urihttps://dspace.xmu.edu.cn/handle/2288/93435
dc.descriptionKey Projects of Fujian Province Technology [2010D026]; Medical Innovations Topic in Fujian Province [2012-CXB-29]; Projects of Xiamen Scientific and Technological Plan [3502Z20124018]zh_CN
dc.description.abstractPurpose. Truncated tissue factor (tTF) fusion protein targeting tumor vasculature can induce tumor vascular thrombosis and necrosis. Here, we generated (RGD)(3)-tTF in which three arginine-glycine-aspartic (RGD) targeting integrin alpha(v)beta(3) and tTF induce blood coagulation in tumor vessels. Methods. The bioactivities of (RGD)(3)-tTF including coagulation activity, FX activation, and binding with integrin alpha(v)beta(3) were performed. The fluorescent labeled (RGD)(3)-tTF was intravenously injected into tumor-bearing mice and traced in vivo. The tumor growth, volume, blood vessel thrombosis, tumor necrosis, and survival time of mice treated with (RGD)(3)-tTF were evaluated. Results. The clotting time and FX activation of (RGD)(3)-tTF were similar to that of TF (P > 0.05) but different with that of RGD (P < 0.05). (RGD)(3)-tTF presented a higher binding with alpha(v)beta(3) than that of RGD and TF at the concentration of 0.2 mu mol/L (P < 0.05). (RGD)(3)-tTF could specifically assemble in tumor and be effective in reducing tumor growth by selectively inducing tumor blood vessels thrombosis and tumor necrosis which were absent in mice treated with RGD or TF. The survival time of mice treated with (RGD)(3)-tTF was higher than that of mice treated with TF or RGD(P < 0.05). Conclusion. (RGD)(3)-tTF may be a promising strategy for the treatment of colorectal cancer.zh_CN
dc.language.isoen_USzh_CN
dc.publisherHINDAWI PUBLISHING CORPORATIONzh_CN
dc.source.urihttp://dx.doi.org/10.1155/2013/637086zh_CN
dc.subjectFACTOR FUSION PROTEINSzh_CN
dc.subjectRGD-BASED STRATEGIESzh_CN
dc.subjectTISSUE-FACTORzh_CN
dc.subjectALPHA(V)BETA(3) INTEGRINzh_CN
dc.subjectTUMOR VASCULATUREzh_CN
dc.subjectCANCERzh_CN
dc.subjectALPHA-V-BETA-3zh_CN
dc.subjectDELIVERYzh_CN
dc.subjectPEPTIDEzh_CN
dc.subjectGROWTHzh_CN
dc.titleTargeting the Vasculature of Colorectal Carcinoma with a Fused Protein of (RGD)(3)-tTFzh_CN
dc.typeArticlezh_CN


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record